针对一种以上遗传病的植入前遗传学检测:临床与伦理考量及困境
该研究回顾性分析了荷兰国家植入前遗传学检测中心1995至2018年间全部40例针对一种以上遗传病的植入前遗传学检测申请,其中16对夫妇开始IVF治疗,共进行39个IVF周期,出生5名健康儿童。作者认为组合植入前遗传学检测是可行的扩展,可能需要调整许多国家关于适应症设定的标准,并带来需要及时咨询和信息的复杂选择。
要点
- 组合植入前遗传学检测是可行扩展,可能需调整许多国家关于适应症设定的标准。
- 45%的申请夫妇按感知严重程度区分主要和次要疾病。
- 作者认为对已有植入前遗传学检测适应症的夫妇,次要疾病的「严重疾病高风险」标准应降低。
核心结论
- 组合植入前遗传学检测是植入前遗传学检测实践的可行扩展,可能需要调整许多国家关于适应症设定的标准。
- 作者认为,对于已有植入前遗传学检测适应症的夫妇,次要疾病的「严重疾病高风险」标准应降低。
- 与欧洲人类生殖与胚胎学学会指南一致,移植已知患有所检测疾病的胚胎可能是可接受的,条件是避免儿童生活质量严重下降的高风险。
研究设计与样本
- 回顾性审查荷兰国家植入前遗传学检测中心1995至2018年间全部40例针对一种以上遗传病的植入前遗传学检测申请。
- 该数据涵盖荷兰自植入前遗传学检测开始以来的所有相关国家数据。
- 通过审查申请组合植入前遗传学检测的夫妇的医疗档案收集数据。
- 结合多个欧洲国家的植入前遗传学检测法规以及欧洲人类生殖与胚胎学学会关于适应症设定和移植决策的相关指南,探讨组合植入前遗传学检测带来的伦理挑战。
主要发现
- 报告40对夫妇申请组合植入前遗传学检测,其中16对夫妇开始IVF治疗。
- 这16对夫妇共进行39个IVF周期,出生5名健康儿童。
- 申请组合植入前遗传学检测的夫妇中,45%按感知严重程度区分主要和次要疾病。
关键数值与推荐
- 作者认为,许多国家作为适应症设定依据的「严重疾病高风险」标准,对于已有植入前遗传学检测适应症的夫妇的次要疾病应降低。
- 与欧洲人类生殖与胚胎学学会指南一致,移植已知患有所检测疾病的胚胎可能是可接受的,条件是避免儿童生活质量严重下降的高风险。
临床怎么用
- 组合植入前遗传学检测需要及时的咨询和信息,以应对复杂的抉择。
- 作者建议调整许多国家关于植入前遗传学检测适应症设定的标准,对已有适应症的夫妇降低次要疾病的「严重疾病高风险」标准。
- 作者认为,与欧洲人类生殖与胚胎学学会指南一致,移植已知患有所检测疾病的胚胎可能是可接受的,条件是避免儿童生活质量严重下降的高风险。
- 作者指出,随着植入前遗传学检测中基因组分析通用方法的引入将经常产生偶然发现,导致带有相同挑战的移植请求,因此本讨论的重要性超出当前组合植入前遗传学检测的讨论。
局限性
- 作者报告这是首个组合植入前遗传学检测治疗概述。
- 回顾性分析使用国家数据,可能不反映当前世界范围趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Which clinical and ethical aspects of preimplantation genetic testing for monogenic disorders or structural rearrangements (PGT-M, PGT-SR) should be considered when accepting requests and counselling couples for PGT when applied for more than one condition (combination-PGT; cPGT-M/SR)? SUMMARY ANSWER: cPGT is a feasible extension of the practice of PGT-M/SR that may require adapting the criteria many countries have in place with regard to indications-setting for PGT-M/SR, while leading to complex choices that require timely counselling and information. WHAT IS KNOWN ALREADY: Although PGT-M/SR is usually performed to prevent transmission of one disorder, requests for PGT-M/SR for more than one condition (cPGT-M/SR) are becoming less exceptional. However, knowledge about implications for a responsible application of such treatments is lacking. STUDY DESIGN, SIZE, DURATION: Retrospective review of all (40) PGT-M/SR applications concerning more than one genetic condition over the period 1995-2018 in the files of the Dutch national PGT centre. This comprises all relevant national data since the start of PGT in the Netherlands. PARTICIPANTS/MATERIALS, SETTING AND METHODS: Data regarding cPGT-M/SR cases were collected by means of reviewing medical files of couples applying for cPGT-M/SR. Ethical challenges arising with cPGT-M/SR were explored against the background of PGT-M/SR regulations in several European countries, as well as of relevant ESHRE-guidance regarding both indications-setting and transfer-decisions. MAIN RESULTS AND THE ROLE OF CHANCE: We report 40 couples applying for cPGT-M/SR of which 16 couples started their IVF treatment. Together they underwent 39 IVF cycles leading to the birth of five healthy children. Of the couples applying for cPGT, 45% differentiated between a primary and secondary condition in terms of perceived severity. In the light of an altered balance of benefits and drawbacks, we argue the 'high risk of a serious condition' standard that many countries uphold as governing indications-setting, should be lowered for secondary conditions in couples who already have an indication for PGT-M/SR. As a consequence of cPGT, professionals will more often be confronted with requests for transferring embryos known to be affected with a condition that they were tested for. In line with ESHRE guidance, such transfers may well be acceptable, on the condition of avoiding a high risk of a child with a seriously diminished quality of life. LIMITATIONS, REASONS FOR CAUTION: We are the first to give an overview of cPGT-M/SR treatments. Retrospective analysis was performed using national data, possibly not reflecting current trends worldwide. WIDER IMPLICATIONS OF THE FINDINGS: Our observations have led to recommendations for cPGT-M/SR that may add to centre policy making and to the formulation of professional guidelines. Given that the introduction of generic methods for genomic analysis in PGT will regularly yield incidental findings leading to transfer requests with these same challenges, the importance of our discussion exceeds the present discussion of cPGT. STUDY FUNDING/COMPETING INTEREST(S): The research for this publication was funded by the Dutch Organization for Health Research and Development (ZonMw), project number: 141111002 (Long term safety, quality and ethics of Preimplantation Genetic Diagnosis). None of the authors has any competing interests to declare.
引用
- van der Schoot V, Dondorp W, Dreesen JCFM, et al. Preimplantation genetic testing for more than one genetic condition: clinical and ethical considerations and dilemmas. Hum Reprod. 2019. PMID: 31119284. doi:10.1093/humrep/dez059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。